We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Qualyst and Solvo Biotechnology Announce Alliance for B CLEAR® in Europe

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Solvo Biotechnology and Qualyst, Inc. have announced that Solvo has obtained a license to Qualyst’s B CLEAR® system. B-CLEAR® products and services are projected to be available in Europe from Solvo in early 2008.  Financial details were not disclosed.

B-CLEAR® is a patented system for the in vitro assessment and in vivo prediction of hepatobiliary disposition, hepatic uptake, hepatic efflux, biliary clearance and drug transport. B-CLEAR® offers research organizations the ability to generate physiologically-relevant data and enable decision making in critical areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges.

B-CLEAR® can be used as an early discovery screen for promotion of compounds, as a source of lead optimization guidance, and as a tool to address development-stage drug transport and drug-drug interaction challenges.